Uncontrolled Epstein-Barr Virus as an Atypical Presentation of Deficiency in ADA2 (DADA2)

J Clin Immunol. 2021 Apr;41(3):680-683. doi: 10.1007/s10875-020-00940-1. Epub 2021 Jan 4.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine Deaminase / blood
  • Adenosine Deaminase / deficiency*
  • Antiviral Agents / therapeutic use
  • Biomarkers
  • Biopsy
  • Child
  • DNA Mutational Analysis
  • Disease Management
  • Disease Susceptibility
  • Epstein-Barr Virus Infections / diagnosis*
  • Epstein-Barr Virus Infections / drug therapy
  • Epstein-Barr Virus Infections / etiology*
  • Exome Sequencing
  • Female
  • Hematopoietic Stem Cell Transplantation
  • Humans
  • Intercellular Signaling Peptides and Proteins / blood
  • Intercellular Signaling Peptides and Proteins / deficiency*
  • Severe Combined Immunodeficiency / complications*
  • Severe Combined Immunodeficiency / diagnosis
  • Severe Combined Immunodeficiency / genetics*
  • Severe Combined Immunodeficiency / therapy
  • Siblings
  • Symptom Assessment
  • Tomography, X-Ray Computed
  • Treatment Outcome

Substances

  • Antiviral Agents
  • Biomarkers
  • Intercellular Signaling Peptides and Proteins
  • ADA2 protein, human
  • Adenosine Deaminase